About
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel,...
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
- 4Sep19
- 30Aug19
- 29Aug19
- 29Aug19News Release
Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients - 20Aug19
- 20Aug19
- 11Jul19
- 28Jun19News Release
Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event
- 12Jun19News Release
Immunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST
- 29May19
- 28May19News Release
Immunicum AB (publ) Announces Outcome of Subscription in Employee Incentive Program 2019/2022
- 22May19
- 7May19
- 29Apr19
- 25Apr19News Release
Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019
- 25Apr19
- 25Apr19
- 25Apr19
- 4Apr19
- 3Apr19
- 26Mar19
- 21Feb19
- 15Feb19
- 15Feb19
- 11Feb19News Release
Immunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial
- 31Jan19News Release
Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue
- 30Jan19
- 21Jan19News Release
Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology
- 28Dec18News Release
Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue
- 13Dec18News Release
Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M
- 8Nov18News Release
Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018
- 7Nov18
- 7Nov18
- 7Nov18
- 22Oct18News Release
Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018
- 19Oct18
- 1Oct18News Release
Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration
- 17Sep18News Release
Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board
- 17Aug18
- 17Aug18
- 13Aug18News Release
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress
- 23Jul18News Release
Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial
- 18Jun18News Release
Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research
- 21May18News Release
Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial
- 4May18
- 4May18
- 3Apr18News Release
Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program
- 20Mar18News Release
Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data
- 14Mar18News Release
The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board
